| COMPANY |
Applied Therapeutics, Inc. |
| COURT |
United States District Court for the Southern District of New York |
| CASE NUMBER |
1:24-cv-9715 |
| JUDGE |
The Honorable Denise L. Cote |
| CLASS PERIOD |
January 3, 2024, through December 2, 2024 |
| SECURITY TYPE |
Common Stock |
Case Background:
This is a federal securities fraud class action lawsuit on behalf of all persons and entities that purchased or otherwise acquired Applied Therapeutics, Inc (“Applied”) (NASDAQ: APLT) common stock between January 3, 2024 and December 2, 2024, both dates inclusive (the “Class Period”). The Class Period begins on January 3, 2024, when Applied Therapeutics issued a press release announcing that the company submitted a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for govorestat (AT-007) for the treatment of Classic Galactosemia.
The complaint alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that Applied Therapeutics was not adhering to trial protocol and good clinical practices for its drug candidate, govorestat, which, in turn, created an exceedingly severe risk that the trial data would be rejected by the FDA in the context of an NDA.
Current Status of Case:
Defendants filed Motions to Dismiss the Second Amended Complaint on June 27, 2025. This action is ongoing.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP: Jon Naji, Esq. (484) 270-1453 or via e-mail at info@ktmc.com. If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.